Literature DB >> 8662748

Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase.

E Fournier1, O Rosnet, S Marchetto, C W Turck, R Rottapel, P G Pelicci, D Birnbaum, J P Borg.   

Abstract

The FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which belongs to the family of receptors for vascular endothelial growth factor. As the result of an alternative processing of primary mRNA transcripts, the long isoform differs from the short isoform by an additional stretch of 65 amino acid residues located at the C terminus and containing three tyrosine residues, Tyr1333, Tyr1337, and Tyr1363. Only the long isoform is endowed with a transforming capacity in fibroblasts. We show that this activity is related to the capacity of the tyrosine 1337-containing sequence to interact with the phosphotyrosine binding domain of the SHC protein. This demonstrates that a functional property of this newly described domain includes relay of mitogenic signals. In addition, it shows that the same receptor can mediate different functions through the optional binding of the phosphotyrosine binding domain and that the alternative use of this domain is sufficient to direct the signal toward different pathways.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662748     DOI: 10.1074/jbc.271.22.12956

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc.

Authors:  R Bronson; C Dawe; J Carroll; T Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Lymphangiogenesis and lymphatic metastasis in breast cancer.

Authors:  Sophia Ran; Lisa Volk; Kelly Hall; Michael J Flister
Journal:  Pathophysiology       Date:  2009-12-24

Review 3.  Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.

Authors:  Z Zhu; L Witte
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.651

Review 4.  The role of VEGF receptors in angiogenesis; complex partnerships.

Authors:  S Cébe-Suarez; A Zehnder-Fjällman; K Ballmer-Hofer
Journal:  Cell Mol Life Sci       Date:  2006-03       Impact factor: 9.261

5.  High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer.

Authors:  José Maañón; Diego Perez; Alejandro Rhode; Gonzalo Callejón; Francisco Rivas-Ruiz; Elisabeth Perez-Ruiz; Isabel Rodrigo; Belén Ramos; Francisco Medina; Rosa Villatoro; Maximino Redondo; Antonio Rueda
Journal:  Oncotarget       Date:  2018-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.